Biosimilar Monoclonal Antibodies Market Size, Share, Forecast To 2033
Introduction Biosimilar monoclonal antibodies (mAbs) are biologic drugs designed to be highly similar to already approved reference monoclonal ...
European Medicines Agency (EMA) Validates Henlius and Organon Filing for Perjeta® (pertuzumab) Biosimilar Candidate HLX11
Henlius and Organon announced the European Medicines Agency validates filing for Perjeta® (pertuzumab) Biosimilar Candidate HLX11 ...
Business Wire4d
European Medicines Agency (EMA) Validates Henlius and Organon Filing for Perjeta ® (pertuzumab) Biosimilar Candidate HLX11
To date, the company's launched products include HANLIKANG (rituximab), the first China-developed biosimilar, HANQUYOU (trastuzumab, trade name: HERCESSI in the U.S., Zercepac in Europe), a China ...
Mirage News4d
EMA Validates Henlius, Organon Filing for Perjeta Biosimilar
In 2022, Henlius entered into a license and supply agreement with Organon, granting Organon the exclusive commercialization rights to two biosimilar candidates, including HLX11. The agreement covers ...
pharmaphorum2d
Biosimilars in the UK: where are we now and where does the NHS want to go?
That changed with the next two biosimilars to come online, which were versions of the cancer drugs MabThera (rituximab) and Herceptin (trastuzumab). This time around incentives were put in place ...
Organon, Shanghai Henlius Biotech: EMA validates MAA for HLX11
Shanghai Henlius Biotech and Organon (OGN) announced that the European Medicines Agency has validated the marketing authorization application ...
pharmaphorum1d
FDA rejects Teva/Celltrion biosimilars
The companies filed biosimilars of Roche’s big-selling Rituxan (rituximab) for inflammatory diseases and certain blood cancers, and Herceptin (trastuzumab) for breast and gastrointestinal cancer ...